INTENSITY THERAPEUTICS, INC. Net Income
INTENSITY THERAPEUTICS, INC. (INTS) reported Net Income of -$3.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$3.01M.
- INTENSITY THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$2.43M.
- INTENSITY THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$3.05M.
- INTENSITY THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$2.67M.
- INTENSITY THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2025 was -$11.61M.
- INTENSITY THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2024 was -$16.27M.
- INTENSITY THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2023 was -$10.54M.
- INTENSITY THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2022 was -$7.58M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.01M 10-Q · filed 2026-08-11 | -$5.44M 10-Q · filed 2026-08-11 | -$8.49M derived: sum of 3 quarters · filed 2026-08-11 | -$11.16M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | -$2.43M 10-Q · filed 2026-08-11 | -$5.49M derived: sum of 2 quarters · filed 2026-08-11 | -$8.16M derived: sum of 3 quarters · filed 2026-08-11 | -$10.69M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | -$3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$5.72M derived: sum of 2 quarters · filed 2026-03-27 | -$8.26M derived: sum of 3 quarters · filed 2026-08-11 | -$11.61M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | -$2.67M 10-Q · filed 2025-11-06 | -$5.21M derived: sum of 2 quarters · filed 2026-08-11 | -$8.55M 10-Q · filed 2025-11-06 | -$11.74M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | -$2.54M 10-Q · filed 2026-08-11 | -$5.88M 10-Q · filed 2026-08-11 | -$9.06M derived: sum of 3 quarters · filed 2026-08-11 | -$12.58M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$3.35M 10-Q · filed 2026-08-11 | -$6.53M derived: sum of 2 quarters · filed 2026-08-11 | -$10.04M derived: sum of 3 quarters · filed 2026-08-11 | -$15.01M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2024-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$6.69M derived: sum of 2 quarters · filed 2026-03-27 | -$11.66M derived: sum of 3 quarters · filed 2026-03-27 | -$16.27M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | -$3.51M 10-Q · filed 2025-11-06 | -$8.48M derived: sum of 2 quarters · filed 2025-11-06 | -$13.09M 10-Q · filed 2025-11-06 | -$16.26M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | -$4.97M 10-Q · filed 2025-11-06 | -$9.57M 10-Q · filed 2025-08-07 | -$12.75M derived: sum of 3 quarters · filed 2025-11-06 | -$15.07M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-03-31 | -$4.60M 10-Q · filed 2025-11-06 | -$7.78M derived: sum of 2 quarters · filed 2025-11-06 | -$10.10M derived: sum of 3 quarters · filed 2025-11-06 | -$13.80M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2023-12-31 | -$3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$5.50M derived: sum of 2 quarters · filed 2025-03-13 | -$9.20M derived: sum of 3 quarters · filed 2025-03-13 | -$10.54M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$2.33M 10-Q · filed 2024-11-13 | -$2.33M 10-Q · filed 2023-11-13 | -$6.03M derived: sum of 2 quarters · filed 2024-11-13 | -$7.37M 10-Q · filed 2024-11-13 | -$7.37M 10-Q · filed 2023-11-13 | -$8.88M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$3.70M 10-Q · filed 2024-11-13 | -$3.70M 10-Q · filed 2023-08-14 | -$5.04M 10-Q · filed 2024-08-08 | -$5.04M 10-Q · filed 2023-08-14 | -$6.55M derived: sum of 3 quarters · filed 2024-11-13 | -$8.32M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-03-31 | -$1.34M 10-Q · filed 2024-11-13 | -$2.85M derived: sum of 2 quarters · filed 2024-11-13 | -$4.62M derived: sum of 3 quarters · filed 2024-11-13 | -$6.55M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2022-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$3.29M derived: sum of 2 quarters · filed 2024-03-14 | -$5.21M derived: sum of 3 quarters · filed 2024-03-14 | -$7.58M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$1.77M 10-Q · filed 2023-11-13 | -$3.70M derived: sum of 2 quarters · filed 2023-11-13 | -$6.07M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$1.93M 10-Q · filed 2023-08-14 | -$4.30M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |